The DOI matches its Crossref record.
Immunogenetic and Clinical Characterization of Slowly Progressive IDDM
Open accessAbstract
OBJECTIVE: To examine the clinical and immunogenetic heterogeneity of IDDM. RESEARCH DESIGN AND METHODS: We divided 207 IDDM patients into groups based on the interval from clinical onset to initiation of insulin therapy: group A (<3 mo, acute clinical-onset group, n = 134), group B (3–12 mo, intermediate group, n = 31), and group C (>13 mo, slowly progressive group, n = 42). Immunogenetic and clinical markers were compared between group A and group C. RESULTS: The mode age of onset was higher in group C (52 yr) than group A (10 yr). Group C had a higher prevalence of islet cell antibodies (42.9%, 18 of 42) than group A (25.4%, 34 of 134, P = 0.05). Serum C-peptide immunoreactivity assayed by radioimmunoassay in response to a 100-g oral glucose tolerance test was significantly higher in group C uhan in group A. Group C patients were also more likely to have a family history of NIDDM (26.1%, 11 of 42) among their first-degree relatives than group A patients (11.2%, 15 of 134, P = 0.039). The prevalences of family history of IDDM and endocrine autoimmune diseases were not different between groups C and A. The frequency of complications of endocrine autoimmune disease was not different between group A (6.7%, 9 of 134) and group C (2.3%, 1 of 42). Significant associations with two class I major histocompatibility complex antigens (HLA-A24 and -Bw54) and one class II antigen (HLA-DR4) were observed in group A. Group A patients were assocciated with three diabetogenic HLA-DQ haplotypes including DQA1*0301-DQB1*0401, DQAl*0301-DQBl*0302, and DQA1 *0301-DQB 1*0303. In contrast, group C lacked the association with class I antigens, although HLA-DR4 and HLA-DQA1* 0301-DQB 1*0401 were more common in this group than in control subjects. CONCLUSIONS: These results indicate that the clinical subtype with slowly progressive course (slowly progressive IDDM) has distinct findings including late-age onset, high prevalence of islet cell antibodies, preserved β-cell function, and high family history of NIDDM. An additive effect of class I and class II major histocompatibility complex antigens is suggested as an explanation for the acute clinical manifestations and more severe β-cell destruction in group A patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Turner, R., Stratton, I., Horton, V., Manley, S., Zimmet, P., Mackay, I. R., Shattock, M., Bottazzo, G. F., & Holman, R. (1997) · The Lancet · doi:10.1016/s0140-6736(97)03062-6 · Cited by 779
Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective
Zaccardi, F., Webb, D. R., Yates, T., & Davies, M. J. (2016) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2015-133281 · Cited by 561
Type 2 diabetes mellitus in children and adolescents
Reinehr, T. (2013) · World Journal of Diabetes · doi:10.4239/wjd.v4.i6.270 · Cited by 363
Autoimmune Diabetes Not Requiring Insulin at Diagnosis (Latent Autoimmune Diabetes of the Adult)
Pozzilli, P., & Di Mario, U. (2001) · Diabetes Care · doi:10.2337/diacare.24.8.1460 · Cited by 284
Role of Chemokines in Endocrine Autoimmune Diseases
Rotondi, M., Chiovato, L., Romagnani, S., Serio, M., & Romagnani, P. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0044 · Cited by 257
Metadata
- Authors
- Kobayashi, T., Tamemoto, K., Nakanishi, K., Kato, N., Okubo, M., Kajio, H., Sugimoto, T., Murase, T., & Kosaka, K.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 1993-05-01
- Volume
- 16
- Issue
- 5
- Pages
- 780-788
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W1987661892
- Cited by
- 251
- References
- 0
- FWCI
- 4.65
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immunogenetic and Clinical Characterization of Slowly Progressive IDDM. https://app.cochat.ai/papers/10.2337/diacare.16.5.780
- The paper
- Kobayashi, T., Tamemoto, K., Nakanishi, K., Kato, N., Okubo, M., Kajio, H., Sugimoto, T., Murase, T., & Kosaka, K. (1993). Immunogenetic and Clinical Characterization of Slowly Progressive IDDM. Diabetes Care. https://doi.org/10.2337/diacare.16.5.780
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.